|
WEST BERLIN, N.J.--(BUSINESS
WIRE)--Aug. 17, 2006--EP MedSystems, Inc. (NASDAQ:
EPMD - News), a market leader in
electrophysiology (EP) products used to diagnose and
treat certain types of cardiac rhythm disorders,
today announced that David Bruce will join the
Company as President, Chief Executive Officer and a
member of the Board of Directors. Mr. Bruce will
lead the further commercialization of the Company’s
products and it’s next stage of growth. David
Jenkins, founder and former Chief Executive 0fficer
will continue in his role EP MedSystems’ Chairman.
David Bruce joins EP MedSystems following nine years
of increasing responsibility at Acuson Corporation
and the Ultrasound Division of Siemens including
General Manager of the intracardiac echo (ICE)
catheter group with responsibility for both
commercial operations and research and development.
In partnership with leading electrophysiologists and
interventional cardiologists, Dave’s team developed
and expanded the clinical adoption of ICE for
guidance of advanced catheter-based cardiac
treatments for atrial fibrillation and atrial septal
defects, leading to a five-fold increase of
installed customer sites
and catheter sales revenue during the last four
years.
In addition to cardiovascular ultrasound management,
David’s experience includes serving as Vice
President of Marketing and Business Development for
Excimer Vision Leasing, a provider and manager of
LASIK surgery systems and marketing programs for
ophthalmologists, and in Capital Markets with Bank
of America. He holds a degree in Mechanical
Engineering from U.C. Berkeley and an MBA from The
Wharton School.
“EP MedSystems has made significant progress in the
commercialization of its products, specifically our
ViewMate® intracardiac ultrasound catheter system
and David Bruce will provide the high-quality
experience and strategic direction which we need to
achieve our goal of providing the most advanced
diagnostic, therapeutic and visualization products
to the vast cardiac rhythm management market.”
stated David Jenkins, EP MedSystems’ Chairman. “I
am confident that David’s strong management, sales
and marketing and ultrasound experience will
contribute to the growth of our business. “
David Bruce, the company’s incoming CEO commented,
“As cardiac treatments evolve from open surgery, to
minimally invasive and now catheter-based
procedures, the visualization of these procedures
must also evolve from direct vision, to key-hole
cameras and now to ultrasound catheter imaging –
with its unique ability to deliver live imaging of
anatomy and devices through blood. I joined EP
MedSystems because I’m convinced that the Company is
well positioned to capitalize on the major growth in
catheter-based cardiac procedures in EP and beyond,
and can generate significant value for its
shareholders.”
About EP MedSystems:
EP MedSystems develops and
markets cardiac electrophysiology ("EP") products
used to diagnose and treat certain cardiac rhythm
disorders. The Company's EP product line includes
the EP-WorkMate® Electrophysiology Workstation with
RPM(TM) Real-time Position Management(TM) navigation
technology, the EP-4(TM) Computerized Cardiac
Stimulator, fixed and deflectable diagnostic
electrophysiology catheters and related disposable
supplies, the ALERT® System and ALERT family of
internal cardioversion catheters, and the ViewMate®
intracardiac ultrasound catheter imaging system. For
more information, visit our website at
www.epmedsystems.com.
Forward Looking Statements:
This Release may contain
certain statements of a forward-looking nature
relating to future events or the future financial
performance of the Company. Forward-looking
statements include information concerning our
possible or assumed future results of operations and
statements preceded by, followed by or including the
words "believes", "expects", "anticipates",
"intends", "plans", "estimates", "see opportunities"
or similar expressions. Such forward-looking
statements are based on our management's beliefs and
assumptions and on information currently available
to our management. Such forward-looking statements
are only predictions and are subject to risks and
uncertainties that could cause actual results or
events to differ materially and adversely from the
events discussed in the forward-looking statements.
Factors that could cause or contribute to such
differences include, but are not limited to, EP
MedSystems' history of losses, uncertainty of market
acceptance of our products and level of sales,
uncertainty of future profitability and future
liquidity needs, possible costs, fines or penalties
that may be incurred in connection with government
inquiries and investigations and risks regarding
regulatory approvals and demand for new and existing
products, as stated in the Company's Annual Report
filed on Form 10-K and Quarterly Reports filed on
Form 10-Q.
EP MedSystems cautions investors
and others to review the cautionary statements set
forth in this press release and in EP MedSystems'
reports filed with the Securities and Exchange
Commission and cautions that other factors may prove
to be important in affecting the EP MedSystems'
business and results of operations. Readers are
cautioned not to place undue reliance on this press
release and other forward-looking statements, which
speak only as of the date of this release. EP
MedSystems undertakes no obligation to publicly
release the results of any revisions to these
forward-looking statements that may be made to
reflect events or circumstances after the date of
this report or to reflect the occurrence of
unanticipated events.
###
|
